Home/Filings/4/0001012975-17-000069
4//SEC Filing

ANAPTYSBIO INC 4

Accession 0001012975-17-000069

$ANABCIK 0001370053operating

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 4:16 PM ET

Size

37.8 KB

Accession

0001012975-17-000069

Insider Transaction Report

Form 4
Period: 2017-01-31
Transactions
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+88,709$1,330,63588,709 total(indirect: See footnote)
  • Conversion

    Common Stock

    2017-01-31+209,095209,095 total(indirect: See footnote)
  • Conversion

    Series C Preferred Stock

    2017-01-31604,0550 total
    Common Stock (604,055 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31733,7400 total(indirect: See footnote)
    Common Stock (733,740 underlying)
  • Conversion

    Common Stock

    2017-01-31+1,428,5711,428,571 total
  • Conversion

    Common Stock

    2017-01-31+604,055604,055 total
  • Conversion

    Common Stock

    2017-01-31+733,740733,740 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2017-01-311,428,5710 total
    Common Stock (1,428,571 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2017-01-31195,7510 total
    Common Stock (195,751 underlying)
  • Conversion

    Common Stock

    2017-01-31+195,751195,751 total
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+311,291$4,669,365311,291 total(indirect: See footnote)
  • Conversion

    Series D Preferred Stock

    2017-01-31209,0950 total(indirect: See footnote)
    Common Stock (209,095 underlying)
FHM V, LP
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-01-31+1,428,5711,428,571 total
  • Conversion

    Series B Preferred Stock

    2017-01-311,428,5710 total
    Common Stock (1,428,571 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2017-01-31195,7510 total
    Common Stock (195,751 underlying)
  • Conversion

    Common Stock

    2017-01-31+733,740733,740 total(indirect: See footnote)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+88,709$1,330,63588,709 total(indirect: See footnote)
  • Conversion

    Series C Preferred Stock

    2017-01-31604,0550 total
    Common Stock (604,055 underlying)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+311,291$4,669,365311,291 total(indirect: See footnote)
  • Conversion

    Common Stock

    2017-01-31+604,055604,055 total
  • Conversion

    Series D Preferred Stock

    2017-01-31733,7400 total(indirect: See footnote)
    Common Stock (733,740 underlying)
  • Conversion

    Common Stock

    2017-01-31+195,751195,751 total
  • Conversion

    Common Stock

    2017-01-31+209,095209,095 total(indirect: See footnote)
  • Conversion

    Series D Preferred Stock

    2017-01-31209,0950 total(indirect: See footnote)
    Common Stock (209,095 underlying)
FHM V, LLC
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-01-31+195,751195,751 total
  • Conversion

    Common Stock

    2017-01-31+733,740733,740 total(indirect: See footnote)
  • Conversion

    Common Stock

    2017-01-31+209,095209,095 total(indirect: See footnote)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+311,291$4,669,365311,291 total(indirect: See footnote)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+88,709$1,330,63588,709 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2017-01-311,428,5710 total
    Common Stock (1,428,571 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31733,7400 total(indirect: See footnote)
    Common Stock (733,740 underlying)
  • Conversion

    Common Stock

    2017-01-31+1,428,5711,428,571 total
  • Conversion

    Common Stock

    2017-01-31+604,055604,055 total
  • Conversion

    Series C Preferred Stock

    2017-01-31604,0550 total
    Common Stock (604,055 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2017-01-31195,7510 total
    Common Stock (195,751 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31209,0950 total(indirect: See footnote)
    Common Stock (209,095 underlying)
Transactions
  • Conversion

    Common Stock

    2017-01-31+1,428,5711,428,571 total
  • Conversion

    Common Stock

    2017-01-31+195,751195,751 total
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+88,709$1,330,63588,709 total(indirect: See footnote)
  • Conversion

    Series C-1 Preferred Stock

    2017-01-31195,7510 total
    Common Stock (195,751 underlying)
  • Conversion

    Common Stock

    2017-01-31+604,055604,055 total
  • Conversion

    Common Stock

    2017-01-31+733,740733,740 total(indirect: See footnote)
  • Conversion

    Common Stock

    2017-01-31+209,095209,095 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2017-01-311,428,5710 total
    Common Stock (1,428,571 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31733,7400 total(indirect: See footnote)
    Common Stock (733,740 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31209,0950 total(indirect: See footnote)
    Common Stock (209,095 underlying)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+311,291$4,669,365311,291 total(indirect: See footnote)
  • Conversion

    Series C Preferred Stock

    2017-01-31604,0550 total
    Common Stock (604,055 underlying)
Transactions
  • Conversion

    Series D Preferred Stock

    2017-01-31209,0950 total(indirect: See footnote)
    Common Stock (209,095 underlying)
  • Conversion

    Common Stock

    2017-01-31+604,055604,055 total
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+311,291$4,669,365311,291 total(indirect: See footnote)
  • Conversion

    Series C Preferred Stock

    2017-01-31604,0550 total
    Common Stock (604,055 underlying)
  • Conversion

    Common Stock

    2017-01-31+1,428,5711,428,571 total
  • Conversion

    Common Stock

    2017-01-31+195,751195,751 total
  • Conversion

    Common Stock

    2017-01-31+209,095209,095 total(indirect: See footnote)
  • Conversion

    Common Stock

    2017-01-31+733,740733,740 total(indirect: See footnote)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+88,709$1,330,63588,709 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2017-01-311,428,5710 total
    Common Stock (1,428,571 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2017-01-31195,7510 total
    Common Stock (195,751 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31733,7400 total(indirect: See footnote)
    Common Stock (733,740 underlying)
Transactions
  • Conversion

    Series B Preferred Stock

    2017-01-311,428,5710 total
    Common Stock (1,428,571 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2017-01-31195,7510 total
    Common Stock (195,751 underlying)
  • Conversion

    Common Stock

    2017-01-31+1,428,5711,428,571 total
  • Conversion

    Common Stock

    2017-01-31+604,055604,055 total
  • Conversion

    Series D Preferred Stock

    2017-01-31209,0950 total(indirect: See footnote)
    Common Stock (209,095 underlying)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+311,291$4,669,365311,291 total(indirect: See footnote)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+88,709$1,330,63588,709 total(indirect: See footnote)
  • Conversion

    Common Stock

    2017-01-31+209,095209,095 total(indirect: See footnote)
  • Conversion

    Series C Preferred Stock

    2017-01-31604,0550 total
    Common Stock (604,055 underlying)
  • Conversion

    Common Stock

    2017-01-31+195,751195,751 total
  • Conversion

    Common Stock

    2017-01-31+733,740733,740 total(indirect: See footnote)
  • Conversion

    Series D Preferred Stock

    2017-01-31733,7400 total(indirect: See footnote)
    Common Stock (733,740 underlying)
Naini Nader J
10% Owner
Transactions
  • Conversion

    Common Stock

    2017-01-31+1,428,5711,428,571 total
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+311,291$4,669,365311,291 total(indirect: See footnote)
  • Purchase

    Common Stock

    2017-01-31$15.00/sh+88,709$1,330,63588,709 total(indirect: See footnote)
  • Conversion

    Common Stock

    2017-01-31+604,055604,055 total
  • Conversion

    Common Stock

    2017-01-31+195,751195,751 total
  • Conversion

    Common Stock

    2017-01-31+209,095209,095 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2017-01-311,428,5710 total
    Common Stock (1,428,571 underlying)
  • Conversion

    Series C Preferred Stock

    2017-01-31604,0550 total
    Common Stock (604,055 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2017-01-31195,7510 total
    Common Stock (195,751 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31733,7400 total(indirect: See footnote)
    Common Stock (733,740 underlying)
  • Conversion

    Series D Preferred Stock

    2017-01-31209,0950 total(indirect: See footnote)
    Common Stock (209,095 underlying)
  • Conversion

    Common Stock

    2017-01-31+733,740733,740 total(indirect: See footnote)
Footnotes (7)
  • [F1]The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
  • [F2]The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
  • [F3]The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
  • [F4]The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
  • [F5]Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
  • [F6]Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
  • [F7]Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

Issuer

ANAPTYSBIO INC

CIK 0001370053

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001370053

Filing Metadata

Form type
4
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 4:16 PM ET
Size
37.8 KB